DOCSLIB.ORG

USP Reference Standards Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
USP Reference Standards Catalog Last Updated On: November 7, 2020 USP Reference Standards Catalog Catalog Status RS Name Current Previous Lot CAS # NDC # Unit Co. Of Material UN # Net Unit Commodity Special Pkg. USMCA KORUS Base Base # Lot (VUD) Price Origin Origin Weight Of Codes Restriction Type Eligible Eligible Control Control Measur (HS Codes)* Drug Drug % e 1000408 Active Abacavir Sulfate (200 R108M0 R028L0 (30- 188062- N/A $245.00 GB Chemical 200 mg 2933595960 No No mg) JUN-2020) 50-2 Synthesis 1000419 Active Abacavir Sulfate F0G248 188062- N/A $760.00 IN Chemical 20 mg 2933595960 No No Racemic (20 mg) (4- 50-2 Synthesis [2-amino-6- (cyclopropylamino)- 9H-purin-9yl]-2- cyclopentene-1- methanol sulfate (2:1)) 1000420 Active Abacavir Related F1L311 F0H284 (31- 906626- N/A $877.00 IN Chemical 20 mg 2933599550 No No Compound A (20 mg) OCT-2013) 51-5 Synthesis ([4-(2,6-diamino-9H- purin-9-yl)cyclopent- 2-enyl]methanol) 1000437 Active Abacavir Related F0M143 N/A N/A $877.00 IN Chemical 20 mg 2933599550 No No Compound D (20 mg) Synthesis (N6-Cyclopropyl-9- {(1R,4S)-4-[(2,5- diamino-6- chlorpyrimidin-4- yloxy)methyl] cyclopent-2-enyl}-9H- purine-2,6-diamine) 1000441 Active Abacavir Related F1L318 F0H283 (31- N/A N/A $877.00 IN Chemical 20 mg 2933599550 No No Compound B (20 mg) OCT-2013) Synthesis ([4-(2,5-diamino-6- chloropyrimidin-4- ylamino)cyclopent-2- enyl]methanol) 1000452 Active Abacavir Related F1L322 F0H285 (30- 172015- N/A $960.00 IN Chemical 20 mg 2933599550 No No Compound C (20 mg) SEP-2013) 79-1 Synthesis ([(1S,4R)-4-(2-amino- 6-chloro-9H-purin-9- yl)cyclopent-2- enyl]methanol hydrochloride) 1000485 Active Abacavir Related R077P0 R039P0 (31- N/A N/A $877.00 IN Chemical 15 mg 3822000002 No No Compounds Mixture AUG-2018) Synthesis (15 mg) 1000496 Active Abacavir R077N0 R044D0 (30- N/A N/A $877.00 IN Chemical 15 mg 2933595960 No No Stereoisomers APR-2018) Synthesis Mixture (15 mg) 1000500 Active Abacavir System R066P0 F0J097 (30- N/A N/A $814.00 GB Chemical 15 mg 2933595960 No No Suitability Mixture (15 APR-2018) Synthesis mg) (A mixture containing abacavir sulfate and trans- abacavir) 1000521 Active Acarbose (200 mg) R080U0 F0M160 (31- 56180-94- N/A $300.00 DE Fermentation- 200 mg 2933998350 No No (COLD SHIPMENT OCT-2019) 0 Microbial REQUIRED) 1000532 Active Acarbose System R138L0 F0L204 (30- N/A N/A $767.00 DE Fermentation 2 mg 3822000002 No No Suitability Mixture (2 APR-2021) mg) (COLD Page 1 Last Updated On: November 7, 2020 USP Reference Standards Catalog Catalog Status RS Name Current Previous Lot CAS # NDC # Unit Co. Of Material UN # Net Unit Commodity Special Pkg. USMCA KORUS Base Base # Lot (VUD) Price Origin Origin Weight Of Codes Restriction Type Eligible Eligible Control Control Measur (HS Codes)* Drug Drug % e SHIPMENT REQUIRED) (A mixture containing acarbose and impurities A, B, C, D, E, F and G) 1000554 Active Acamprosate F0M484 77337-73- N/A $245.00 CN Chemical 200 mg 2924190002 No No Calcium (200 mg) 6 Synthesis 1000565 Active Acamprosate Related F0M499 3687-18-1 N/A $730.00 CN Chemical 15 mg 2921196190 No No Compound A (15 mg) Synthesis (3-aminopropane-1- sulfonic acid) 1000576 Active Acamprosate Related F04090 N/A N/A $777.00 IN Chemical 20 mg 2924190002 No No Compound B (20 mg) Synthesis 1000601 Active Acebutolol F005N2 F-1 (31-JUL- 34381-68- N/A $245.00 GB Chemical 125 mg 2924296000 No No Hydrochloride (125 2015) 5 Synthesis mg) 1000612 Active Acebutolol Related R113R0 F1G041 (30- 40188-45- N/A $775.00 ES Chemical 20 mg 2924296000 No No Compound A (20 mg) NOV-2019) 2 Synthesis (N-(3-Acetyl-4- hydroxyphenyl)butyra mide) 1000623 Active Acebutolol Related F005G0 22568-64- N/A $775.00 IN Fermentation 20 mg 2933599550 No No Compound B (20 mg) 5 (N-{3-Acetyl-4-[2- hydroxy-3- (isopropylamino)prop oxy]phenyl}acetamide ) 1000699 Active Acebutolol Related F005H0 441019- N/A $775.00 IN Chemical 20 mg 2924296000 No No Compound I (20 mg) 91-6 Synthesis (N-{3-Acetyl-4-[3- (ethylamino)-2- hydroxypropoxy]phen yl}butyramide) 1000818 Active Abiraterone Acetate R078C0 F029L0 (29- 154229- N/A $965.00 BE Chemical 200 mg 2937290000 No No (200 mg) FEB-2020) 18-2 Synthesis 1000829 Active Abiraterone System R103B0 R065J0 (29- N/A N/A $853.00 BE Chemical 20 mg 3822000002 No No Suitability Mixture (20 FEB-2020) Synthesis mg) 1001502 Active Acepromazine R003N0 F-2 (31-OCT- 3598-37-6 N/A $245.00 IE Chemical 250 mg 2934302300 No No Maleate (250 mg) 2015) Synthesis 1002505 Active Acesulfame G0H082 F0C136 (30- 55589-62- N/A $410.00 CH Chemical 200 mg 2934990002 No No Potassium (200 mg) JUN-2009) 3 Synthesis 1002811 Active Acetaldehyde (3 x 1.1 R08610 (31- 75-07-0 N/A $240.00 UN1089 3.3 mL 2912120000 No No mL) MAR-2021) 1003009 Active Acetaminophen (400 K2M244 K0I244 (30- 103-90-2 N/A $245.00 US Chemical 400 mg 2924296000 No Yes mg) APR-2017) Synthesis 1003010 Active Acetaminophen R107A0 F0J252 (31- 2623-33-8 N/A $775.00 CA Chemical 15 mg 2924296000 No No Related Compound A JUL-2020) Synthesis (15 mg) (4- (acetylamino)phenyl acetate) Page 2 Last Updated On: November 7, 2020 USP Reference Standards Catalog Catalog Status RS Name Current Previous Lot CAS # NDC # Unit Co. Of Material UN # Net Unit Commodity Special Pkg. USMCA KORUS Base Base # Lot (VUD) Price Origin Origin Weight Of Codes Restriction Type Eligible Eligible Control Control Measur (HS Codes)* Drug Drug % e 1003027 Active Acetaminophen R066W R012P0 (28- 1693-37-4 N/A $775.00 RU Chemical 30 mg 2924296000 No No Related Compound B 0 FEB-2019) Synthesis (30 mg) (N-(4- hydroxyphenyl)propa namide) 1003031 Active Acetaminophen R00920 F1M247 (31- 614-80-2 N/A $775.00 DE Chemical 50 mg 2924296000 No No Related Compound C AUG-2015) Synthesis (50 mg) (N-(2- hydroxyphenyl)aceta mide) 1003042 Active Acetaminophen R01300 F0L221 (30- 103-84-4 N/A $775.00 CN Chemical 50 mg 2924296000 No No Related Compound D SEP-2016) Synthesis (50 mg) (N- phenylacetamide) 1003064 Active Acetaminophen F0M236 100-02-7 N/A $775.00 JP Chemical UN1663 50 mg 2908999502 No No Related Compound F Synthesis (50 mg) (p- nitrophenol) 1003100 Active Acetaminophen R11340 R00310 (01- 539-03-7 N/A $775.00 US Chemical 50 mg 2924296000 No No Related Compound J AUG-2019) Synthesis (50 mg) (N-(4- chlorophenyl)acetami de) 1004001 Active Acetanilide Melting R123F0 M2M285 (31- 103-84-4 N/A $165.00 CN Chemical 1 g 2924296000 No No Point Standard (1g) DEC-2020) Synthesis (Approximately 114 degrees) 1005004 Active Acetazolamide (2 g) R089P0 K1J032 (30- 59-66-5 N/A $245.00 PL Chemical 2 g 2935904000 No No SEP-2019) Synthesis 1005048 Active Acetazolamide F025E1 F025E0 (31- 14949-00- N/A $835.00 CN Chemical 25 mg 2935909550 No No Related Compound D AUG-2021) 9 Synthesis (25 mg) (5-Amino- 1,3,4-thiadiazole-2- sulfonamide) 1005059 Active Acetazolamide F025H0 N/A N/A $877.00 CA Chemical 25 mg 2935909550 No Yes Related Compound E Synthesis (25 mg) (5- Acetamido-1,3,4- thiadiazole-2-sulfonic acid potassium salt) 1005706 Active Glacial Acetic Acid R038A0 I0M342 (31- 64-19-7 N/A $280.00 US Chemical UN2789 4.5 mL 2915210000 No Yes (1.5 mL/ampule; 3 JUL-2017) Synthesis ampules) 1006506 Active Acetohydroxamic F-1 (31-OCT- 546-88-3 N/A $230.00 200 mg 2928003000 No No Acid (200 mg) 2020) 1006801 Active Acetone (1.5 I0M548 H0K208 (31- 67-64-1 N/A $265.00 US Chemical UN1090 4.5 mL 2914110000 No Yes mL/ampule; 3 MAR-2017) Synthesis ampules) 1008501 Active Acetylcholine R124K0 R023K0 (28- 60-31-1 N/A $245.00 US Chemical 200 mg 2923900100 No No Chloride (200 mg) FEB-2021) Synthesis 1009005 Active Acetylcysteine (200 R10200 K0K294 (30- 616-91-1 N/A $245.00 CN Animal-Bird 200 mg 2930904915 No No mg) NOV-2019) 1009479 Active 2-Acetylpyridine (1 g) F0K307 1122-62-9 N/A $225.00 CN Chemical 1 g 2933399090 No No Synthesis Page 3 Last Updated On: November 7, 2020 USP Reference Standards Catalog Catalog Status RS Name Current Previous Lot CAS # NDC # Unit Co. Of Material UN # Net Unit Commodity Special Pkg. USMCA KORUS Base Base # Lot (VUD) Price Origin Origin Weight Of Codes Restriction Type Eligible Eligible Control Control Measur (HS Codes)* Drug Drug % e 1009901 Active Acetyltributyl Citrate R053A0 H0I337 (31- 77-90-7 N/A $275.00 US Chemical UN3082 600 mg 2918150000 No Yes (3 x 200 mg) AUG-2017) Synthesis 1009923 Active Acetyltriethyl Citrate R041M0 H0I339 (31- 77-89-4 N/A $275.00 US Chemical 500 mg 2918150000 No Yes (500 mg) JAN-2017) Synthesis 1009978 Active N-Acetyl-D,L- F03581 F03580 (31- 1115-47-5 N/A $285.00 FR Fermentation- 100 mg 2930909165 No No Methionine (100 mg) JAN-2020) Chemical (N-Acetylmethionine) Synthesis 1010022 Active N-Acetylglucosamine F0L512 7512-17-6 N/A $215.00 CN Animal- 200 mg 2932999000 No No (200 mg) Shrimp 1010081 Active N-Acetyl-L-Leucine F046G0 1188-21-2 N/A $245.00 GB Chemical 100 mg 2924190002 No No (100 mg) (Acetyl-L- Synthesis leucine) 1010106 Active N-Acetyl-L-Tyrosine R084G0 F0I085 (31- 537-55-3 N/A $245.00 JP Chemical 100 mg 2924296000 No No (100 mg) OCT-2020) Synthesis 1010208 Active Acetyl Simvastatin F00660 145576- N/A $760.00 IN Chemical 30 mg 2932206000 No No (30 mg) 25-6 Synthesis ((1S,3R,7S,8S,8aR)- 8-{2-[(2R,4R)-4- (acetoxy)-6- oxotetrahydro-2H- pyran-2-yl]ethyl}-3,7- dimethyl-1,2,3,7,8,8a- hexahydronaphthalen -1-yl 2,2- dimethylbutanoate) 1011007 Active Acitretin (200 mg) R04460 F0E266 (31- 55079-83- N/A $575.00 MX Chemical UN3077 200 mg 2918992090 No No JAN-2017) 9 Synthesis 1011018 Active Acitretin Related R13300 F0E264 (31- 69427-46- N/A $785.00 CN Chemical 20 mg 2918992090 No No Compound A (20 mg) JAN-2021) 9 Synthesis ((2Z,4E,6E,8E)-9-(4- Methoxy-2,3,6- trimethylphenyl)-3,7- dimethylnona-2,4,6,8- tetraenoic acid) 1011029
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski Et Al
    USOO9421 180B2 (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski et al. (45) Date of Patent: Aug. 23, 2016 (54) ANTIOXIDANT COMPOSITIONS FOR 6,203,817 B1 3/2001 Cormier et al. .............. 424/464 TREATMENT OF INFLAMMATION OR 6,323,232 B1 1 1/2001 Keet al. ............ ... 514,408 6,521,668 B2 2/2003 Anderson et al. ..... 514f679 OXIDATIVE DAMAGE 6,572,882 B1 6/2003 Vercauteren et al. ........ 424/451 6,805,873 B2 10/2004 Gaudout et al. ....... ... 424/401 (71) Applicant: Perio Sciences, LLC, Dallas, TX (US) 7,041,322 B2 5/2006 Gaudout et al. .............. 424/765 7,179,841 B2 2/2007 Zielinski et al. .. ... 514,474 (72) Inventors: Jan Zielinski, Vista, CA (US); Thomas 2003/0069302 A1 4/2003 Zielinski ........ ... 514,452 Russell Moon, Dallas, TX (US); 2004/0037860 A1 2/2004 Maillon ...... ... 424/401 Edward P. Allen, Dallas, TX (US) 2004/0091589 A1 5, 2004 Roy et al. ... 426,265 s s 2004/0224004 A1 1 1/2004 Zielinski ..... ... 424/442 2005/0032882 A1 2/2005 Chen ............................. 514,456 (73) Assignee: Perio Sciences, LLC, Dallas, TX (US) 2005, 0137205 A1 6, 2005 Van Breen ..... 514,252.12 2005. O154054 A1 7/2005 Zielinski et al. ............. 514,474 (*) Notice: Subject to any disclaimer, the term of this 2005/0271692 Al 12/2005 Gervasio-Nugent patent is extended or adjusted under 35 et al. ............................. 424/401 2006/0173065 A1 8/2006 BeZwada ...................... 514,419 U.S.C. 154(b) by 19 days. 2006/O193790 A1 8/2006 Doyle et al.
    [Show full text]
  • USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements
    USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements U.S. PHARMACOPEIAL CONVENTION The United States Pharmacopeial Convention Urges Scientific Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements (Rockville, MD – April 16, 2015) – In response to an agreement announced between the New York State Attorney General (NYAG) and GNC Holdings, Inc. (GNC) the United States Pharmacopeial Convention (USP), an independent, science based, standards setting organization and publishers of the United States Pharmacopeia-National Formulary (USP-NF), an official compendia of quality standards for dietary supplements sold in the U.S., issued the following statement: Statement by Gabriel Giancaspro, PhD – Vice President –Foods, Dietary Supplement and Herbal Medicines United States Pharmacopeial Convention (USP) “As a science-based standards-setting organization, the United States Pharmacopeial Convention (USP) has a keen interest in adopting emerging technologies to ensure the test methods and quality standards included in the United States Pharmacopeia-National Formulary (USP-NF) are current and reflect the state of the industry. DNA testing including DNA Barcoding, is just one example of a technology that has been recently added to the USP-NF. As of December 2014, DNA-based identification methods are included in the official USP chapter <563> Identification of Articles of Botanical Origin. However, this method is not yet referenced in a USP-NF monograph (quality standard) for a specific ingredient or product. That is because USP quality standards are specific for each ingredient, product and dosage form and the standards we develop include only those test methods that have been scientifically validated and shown to be fit for purpose.
    [Show full text]
  • Research Publications by DISTINCTIONS Any Scientist of Pakistan in Last 10 Year and SERVICES  Secretary General, the Chemical Society of Pakistan
    CV and List of Publications PROF. DR. MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-ei-Imtiaz) International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry, Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi, Karachi-75270 Pakistan Tel: (92-21) 34824924, 34824925 Fax: 34819018, 34819019 E-mail: [email protected] Web Page: www.iccs.edu Biodata and List of Publications Pag No. 2 MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-e-Imtiaz) D-131, Phase II, D. O. H. S., Malir Cant., Karachi-75270, Pakistan Ph.: 92-21-4901110 MAILING INTERNATIONAL CENTER FOR CHEMICAL AND BIOLOGICAL SCIENCES ADDRESS (H. E. J. Research Institute of Chemistry Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi Karachi-74270, Pakistan Tel: (92-21) 34824924-5 Fax: (92-21) 34819018-9 Email: [email protected] Web: www.iccs.edu DATE OF BIRTH September 11, 1959 (Karachi, Pakistan) EDUCATION Doctor of Science (D.Sc.) (University of Karachi ) 2005 Ph.D. (Organic Chemistry) 1987 H. E. J. Research Institute of Chemistry University of Karachi, Karachi-75270, Pakistan Thesis Title: "The Isolation and Structural Studies on Some Medicinal Plants of Pakistan, Buxus papillosa, Catharanthus roseus, and Cissampelos pareira." M.Sc. (Organic Chemistry) 1983 University of Karachi, Karachi-75270, Pakistan B.Sc. (Chemistry, Biochemistry, Botany) 1980 University of Karachi, Karachi-75270, Pakistan AWARDS & Declared as the top most scientist (Number 1) among 1,650 HONORS scientists of Pakistan in all disciplines / fields of science and technology (year 2012) by the Pakistan Council for Science and Technology (Ministry of Science and Technology), Pakistan.
    [Show full text]
  • Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs That Modulate Farnesoid X Receptor
    OPEN Quantitative High-Throughput Profiling of SUBJECT AREAS: Environmental Chemicals and Drugs that SCREENING SMALL MOLECULES Modulate Farnesoid X Receptor Chia-Wen Hsu1, Jinghua Zhao1, Ruili Huang1, Jui-Hua Hsieh2, Jon Hamm3, Xiaoqing Chang3, Keith Houck4 Received & Menghang Xia1 27 June 2014 Accepted 1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, 2Division of the National 29 August 2014 Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 3Integrated Laboratory Systems, Inc., Morrisville, NC, 4U.S. Environmental Protection Agency, Research Triangle Park, NC. Published 26 September 2014 The farnesoid X receptor (FXR) regulates the homeostasis of bile acids, lipids, and glucose. Because endogenous chemicals bind and activate FXR, it is important to examine which xenobiotic compounds Correspondence and would disrupt normal receptor function. We used a cell-based human FXR b-lactamase (Bla) reporter gene assay to profile the Tox21 10K compound collection of environmental chemicals and drugs. requests for materials Structure-activity relationships of FXR-active compounds revealed by this screening were then compared should be addressed to against the androgen receptor, estrogen receptor a, peroxisome proliferator-activated receptors d and c, and M.X. ([email protected]. the vitamin D receptor. We identified several FXR-active structural classes including anthracyclines, gov) benzimidazoles, dihydropyridines, pyrethroids, retinoic acids, and vinca alkaloids. Microtubule inhibitors potently decreased FXR reporter gene activity. Pyrethroids specifically antagonized FXR transactivation. Anthracyclines affected reporter activity in all tested assays, suggesting non-specific activity. These results provide important information to prioritize chemicals for further investigation, and suggest possible modes of action of compounds in FXR signaling.
    [Show full text]
  • Curcumin in Autoimmune and Rheumatic Diseases
    nutrients Review Curcumin in Autoimmune and Rheumatic Diseases Melissa Yang, Umair Akbar and Chandra Mohan * Department of Biomedical Engineering, University of Houston, 3517 Cullen Blvd, Room 2004, Houston, TX 77204, USA; [email protected] (M.Y.); [email protected] (U.A.) * Correspondence: [email protected]; Tel.: 713-743-3709 Received: 29 March 2019; Accepted: 24 April 2019; Published: 2 May 2019 Abstract: Over recent decades, many clinical trials on curcumin supplementation have been conducted on various autoimmune diseases including osteoarthritis, type 2 diabetes, and ulcerative colitis patients. This review attempts to summarize the highlights from these clinical trials. The efficacy of curcumin either alone or in conjunction with existing treatment was evaluated. Sixteen clinical trials have been conducted in osteoarthritis, 14 of which yielded significant improvements in multiple disease parameters. Eight trials have been conducted in type 2 diabetes, all yielding significant improvement in clinical or laboratory outcomes. Three trials were in ulcerative colitis, two of which yielded significant improvement in at least one clinical outcome. Additionally, two clinical trials on rheumatoid arthritis, one clinical trial on lupus nephritis, and two clinical trials on multiple sclerosis resulted in inconclusive results. Longer duration, larger cohort size, and multiple dosage arm trials are warranted to establish the long term benefits of curcumin supplementation. Multiple mechanisms of action of curcumin on these diseases have been researched, including the modulation of the eicosanoid pathway towards a more anti-inflammatory pathway, and the modulation of serum lipid levels towards a favorable profile. Overall, curcumin supplementation emerges as an effective therapeutic agent with minimal-to-no side effects, which can be added in conjunction to current standard of care.
    [Show full text]
  • USP Reference Standards Catalog
    Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction 1000408 Abacavir Sulfate R028L0 F1L487 (12/16) 188062-50-2 $222.00 (200 mg) 1000419 Abacavir Sulfate F0G248 188062-50-2 $692.00 Racemic (20 mg) (4-[2-amino-6-(cyclo propylamino)-9H-pur in-9yl]-2-cyclopenten e-1-methanol sulfate (2:1)) 1000420 Abacavir Related F1L311 F0H284 (10/13) 124752-25-6 $692.00 Compound A (20 mg) ([4-(2,6-diamino-9H- purin-9-yl)cyclopent- 2-enyl]methanol) 1000437 Abacavir Related F0M143 N/A $692.00 Compound D (20 mg) (N6-Cyclopropyl-9-{( 1R,4S)-4-[(2,5-diami no-6-chlorpyrimidin- 4-yloxy)methyl] cyclopent-2-enyl}-9H -purine-2,6-diamine) 1000441 Abacavir Related F1L318 F0H283 (10/13) N/A $692.00 Compound B (20 mg) ([4-(2,5-diamino-6-c Page 1 Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction hloropyrimidin-4-yla mino)cyclopent-2-en yl]methanol) 1000452 Abacavir Related F1L322 F0H285 (09/13) 172015-79-1 $692.00 Compound C (20 mg) ([(1S,4R)-4-(2-amino -6-chloro-9H-purin-9 -yl)cyclopent-2-enyl] methanol hydrochloride) 1000485 Abacavir Related R039P0 F0J094 (11/16) N/A $692.00 Compounds Mixture (15 mg) 1000496 Abacavir F0J102 N/A $692.00 Stereoisomers Mixture (15 mg) 1000500 Abacavir System F0J097 N/A $692.00 Suitability Mixture (15 mg) 1000521 Acarbose (200 mg) F0M160 56180-94-0 $222.00 (COLD SHIPMENT REQUIRED) 1000532 Acarbose System F0L204 N/A $692.00 Suitability
    [Show full text]
  • Small Molecules in Solution Has Rarely Been Reported, However, As a General Guide We Recommend Storage in DMSO at -20°C
    (Z)-Guggulsterone Small Molecules Retinoic acid receptor (RAR) pathway inhibitor; Inhibits farnesoid X receptor (FXR) Catalog # 73702 1 mg Product Description (Z)-Guggulsterone is a plant steroid found in the resin of the guggul plant Commiphora mukul that acts as a selective antagonist of farnesoid X receptor (FXR; Cui et al.). It decreases chenodeoxycholic acid (CDCA)-induced FXR activation (IC ₅₀ = 10 µM) in the presence of 100 µM CDCA (Urizar et al.; Cui et al.). Molecular Name: (Z)-Guggulsterone Alternative Names: Not applicable CAS Number: 39025-23-5 Chemical Formula: C₂₁H₂₈O₂ Molecular Weight: 312.5 g/mol Purity: ≥ 95% Chemical Name: (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15- decahydrocyclopenta[a]phenanthrene-3,16-dione Structure: Properties Physical Appearance: A crystalline solid Storage: Product stable at -20°C as supplied. Protect product from prolonged exposure to light. For long-term storage store with a desiccant. For product expiry date, please contact [email protected]. Solubility: · DMSO ≤ 800 µM · Absolute ethanol ≤ 3.2 µM · DMF ≤ 30 mM For example, to prepare a 10 mM stock solution in DMF, resuspend 1 mg in 320 μL of DMF. Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application. Compound has low solubility in aqueous media.
    [Show full text]
  • Guggulsterones and Levels
    Cholesterol, Guggulsterones and levels. Because normal levels of serum lipids, Bile Production including cholesterol, are supported by increased circulating thyroid hormones, it is believed guggul Much of the cholesterol made by your liver is uti- Guggulsterones works by stimulating the thyroid gland, in addition lized to create bile, a substance used in digestion to its effects on bile production. to emulsify fats. Because excess cholesterol and triglycerides are excreted from our bodies in the Clinically Effective Dosage form of bile, it is important to support the liver’s bile-producing mechanism. According to several clinical studies, the amount of guggulsterones used to maintain Natural Support for Research shows that certain guggul compounds— normal cholesterol levels is 75 mg per day, guggulsterones—help maintain cholesterol levels when taken with a diet low in saturated fats. Cholesterol Health in the normal range and act at the farnesoid X This is the daily dose delivered by SOURCE receptor (FXR) to promote bile production. NATURALS GUGGULSTERONES. Guggulsterones appear to be farnesoid X receptor (FXR) antagonists. FXR is a bile acid receptor. If A Wellness Revolution in FXR is activated, this results in down-regulation Cardiovascular Care of the amount of bile acids produced by the liver. Bile is made out of cholesterol, which gets used up At a time when our cardiovascular health faces when bile is produced. When bile levels are high, numerous lifestyle challenges, research into the the production of more bile is slowed through remarkable heart-supportive properties of the oday’s lifestyle, with its high-fat, processed food diet, lack of exercise, and negative feedback of the FXR pathway.
    [Show full text]
  • Potential of Guggulsterone, a Farnesoid X Receptor Antagonist, In
    Exploration of Targeted Anti-tumor Therapy Open Access Review Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer Sosmitha Girisa , Dey Parama , Choudhary Harsha , Kishore Banik , Ajaikumar B. Kunnumakkara* Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India *Correspondence: Ajaikumar B. Kunnumakkara, Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India. [email protected]; [email protected] Academic Editor: Gautam Sethi, National University of Singapore, Singapore Received: August 8, 2020 Accepted: September 14, 2020 Published: October 30, 2020 Cite this article: Girisa S, Parama D, Harsha C, Banik K, Kunnumakkara AB. Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer. Explor Target Antitumor Ther. 2020;1:313-42. https://doi.org/10.37349/ etat.2020.00019 Abstract Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains a serious concern due to the limitations associated with currently available cancer management strategies. Therefore, alternative strategies are highly required to overcome these glitches. The importance of medicinal plants as primary healthcare has been well-known from time immemorial against various human diseases, including cancer. Commiphora wightii that belongs to Burseraceae family is one such plant which has been used to cure various ailments in traditional systems of medicine.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway
    International Journal of Molecular Sciences Article Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway Patricia Rodríguez Castaño 1,2, Shaheena Parween 1,2 and Amit V Pandey 1,2,* 1 Pediatric Endocrinology, Diabetology, and Metabolism, University Children’s Hospital Bern, 3010 Bern, Switzerland; [email protected] (P.R.C.); [email protected] (S.P.) 2 Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland * Correspondence: [email protected]; Tel.: +41-31-632-9637 Received: 5 September 2019; Accepted: 16 September 2019; Published: 17 September 2019 Abstract: Turmeric, a popular ingredient in the cuisine of many Asian countries, comes from the roots of the Curcuma longa and is known for its use in Chinese and Ayurvedic medicine. Turmeric is rich in curcuminoids, including curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Curcuminoids have potent wound healing, anti-inflammatory, and anti-carcinogenic activities. While curcuminoids have been studied for many years, not much is known about their effects on steroid metabolism. Since many anti-cancer drugs target enzymes from the steroidogenic pathway, we tested the effect of curcuminoids on cytochrome P450 CYP17A1, CYP21A2, and CYP19A1 enzyme activities. When using 10 µg/mL of curcuminoids, both the 17α-hydroxylase as well as 17,20 lyase activities of CYP17A1 were reduced significantly. On the other hand, only a mild reduction in CYP21A2 activity was observed. Furthermore, CYP19A1 activity was also reduced up to ~20% of control when using 1–100 µg/mL of curcuminoids in a dose-dependent manner. Molecular docking studies confirmed that curcumin could dock onto the active sites of CYP17A1, CYP19A1, as well as CYP21A2.
    [Show full text]
  • WO 2013/163758 Al 7 November 2013 (07.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/163758 Al 7 November 2013 (07.11.2013) P O P C T (51) International Patent Classification: (72) Inventor; and A61K 31/416 (2006.01) C12Q 1/00 (2006.01) (71) Applicant : BOYD, Shelley Romayne [CA/CA]; Unit A61P 27/02 (2006.01) A61B 3/10 (2006.01) 2106, 112 George Street, Toronto, Ontario M5A 2M5 (CA). (21) International Application Number: PCT/CA2013/050335 (74) Agents: MARLES, Jennifer A. et al; 480-601 West Cor dova Street, Vancouver, British Columbia V6B 1G1 (CA). (22) International Filing Date: 30 April 2013 (30.04.2013) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 61/640,854 1 May 2012 (01.05.2012) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 61/641,393 2 May 2012 (02.05.2012) US ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/693,226 24 August 2012 (24.08.2012) us NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 61/792,436 15 March 2013 (15.03.2013) us RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]